Fas (CD95) is not a killing target; it is downregulated within the engineered T cells to prevent their apoptosis. The drug’s cytotoxicity is directed against PSMA/CA9-positive tumor cells via CAR-mediated T-cell killing, not against Fas-expressing cells.